Background: Cerebral amyloid angiopathy (CAA) typically presents with lobar intracerebral mac-
from all patients participating in the study or from their guardians.
Study population and patient recruitment. We included 2 patient groups: 1) patients with a histologically proven CAA and 2) patients with non-CAA forms of ICH, in which CAA was excluded by tissue examination (control group). Patients were retrospectively identified by electronic database searches for consecutive patients with histologically proven CAA and for patients with histologically proven non-CAA forms of ICH (figure 1). The inclusion criteria for all patients was the availability of an MRI with a T2*-weighted gradient-echo sequence (T2*w). In control cases, evidence of at least 1 acute ICH on MRI and no evidence of CAA in the tissue examination were further recommended. A total of 38 CAA patients (16 male, mean age 70 Ϯ 6.4 years) and 22 control patients (12 male, mean age 54 Ϯ 18 years) matched the criteria and were included. Three patients of the CAA group have been published previously as a case report. 4
Reference standard. Neuropathologic diagnosis served as the reference standard. It was established based on postmortem brain examination (11 CAA cases, 8 controls), hematoma evacuation (9 CAA cases, 14 controls), or brain biopsy (18 CAA cases). CAA was histologically confirmed by evidence of replacement of vessel walls with amyloid. e1 Available imaging and data analysis. MRI had been performed at 1.5 Tesla MR scanners, including T2*w (slice thick-ness: 5 mm, repetition time: 500 to 1,000 msec, echo time: 13.8 to 25 msec), fluid-attenuated inversion recovery, or proton density-weighted (PDw) images.
Analysis was done in consensus by 2 neuroradiologists with 7 and 12 years experience with analysis of cranial MRI. They were blinded to all clinical and patient information data, including the histopathologic diagnosis. T2*w images were systematically assessed for evidence of ICHs (Ͼ5 mm in diameter), MBs (Ͻ5 mm), 6 and SS. 4 PDw and FLAIR images were used to identify acute subarachnoid hemorrhages (SAH). The distribution of SS and SAH was classified as either focal (restricted to Յ3 sulci) or disseminated (Ն4 sulci). The prevalence of MBs, SS, and acute SAH in both patient groups was calculated in percentages.
To test whether the addition of SS as a criterion alters the sensitivity and specificity of the Boston diagnostic criteria for CAArelated hemorrhage, we proposed the modified Boston criteria, in which SS is regarded as another hemorrhagic manifestation of CAA (table 1). Readers classified the patients according to both the conventional and the modified Boston criteria as possible, probable, or no CAA-related hemorrhage. MBs were also regarded as hemorrhages in terms of the criteria, as this has been shown to increase their sensitivity. 6 The histologic information was not taken into account for the classification. It was assessed in how many cases the modification did influence the classification, and sensitivity and specificity of both sets of criteria were calculated including 95% CIs.
Figure 1 Flow diagram
The retrospective identification of patients with cerebral amyloid angiopathy (CAA) and control patients.
RESULTS
ICHs and MBs were present in 71% and 47.4% of the CAA patients and in 100% and 22.7% of the controls. Acute SAH was observed in 50% of the CAA patients (n ϭ 19). SS was detected in 60.5% of CAA patients. It was focal in 34.2% of patients and disseminated in 26.3% of cases (figure 2). In 6 of the patients with SS no ICHs were present, and in 2 of them SS Ϯ acute SAH were the only magnetic resonance-detectable hemorrhagic lesions, i.e., no MBs were found. In 13 patients with SS and ICH, SS was found not only adjacent to the ICH, but also at sites distant from the ICH. In one patient, SS affected both the supra-and the infratentorial compartment; in all other patients with SS, only the supratentorial sulci were involved. Neither SS nor acute SAH were observed in any of the control cases (table e-1 on the Neurology Web site at www.neurology.org). Inclusion of SS in the Boston criteria resulted in a diagnostic upgrading from no to possible CAArelated hemorrhage in 2 patients (who had SS as the only site of hemorrhage), and from possible to prob-able CAA in 5 patients (who otherwise had only a single ICH). The classic Boston criteria showed a sensitivity of 89.5% (95% CI 75.9 -95.9), while inclusion of SS in the modified criteria increased their sensitivity to 94.7% (95% CI 82.7-98.5). This increase was not significant. The specificity of the Boston criteria was 81.2% (95% CI 61.5-92.7) for the classic as well as for the modified criteria.
DISCUSSION
The main findings in our study were 1) focal or disseminated, supratentorially located SS is commonly present in CAA but not in other types of ICH and 2) inclusion of SS as a criterion resulted in a diagnostic upgrading in 7 patients with CAA, without lowering the specificity of the Boston criteria.
It has been shown in animal models on experimental siderosis that repeated bleeding into the subarachnoid space leads to deposition of hemosiderin in the subpial layer of the brain. 7 Thus, we propose that the same mechanism underlies the pathogenesis of SS observed in CAA, and favor a primary subarachnoid origin of the blood over a secondary spread of ICH into the subarachnoid space in most cases. This hypothesis is supported by the facts that we found SS distant from the localization of any ICH, and that SS was present in 6 patients who did not show any ICH. In accordance with these observations, a neuropathologic study revealed that-at least in some cases of CAA-related subcortical hema-toma-the primary hemorrhage occurred in the subarachnoid space. 8 It has even been suggested that a restricted SAH could be a warning sign, which can precede a lobar ICH in CAA. 9 Compared to the well-described SS of the CNS, which mainly affects brainstem and posterior fossa, 10 SS in CAA showed a preference for the cerebral convexity and only exceptionally occurred in the infratentorial compartment. This explains why patients with CAA lack the typical clinical presentation associated with the previously described form of SS, namely cerebellar and brainstem signs.
To facilitate noninvasive diagnosis of CAA-related hemorrhage, the Boston criteria have been developed in order to provide standardized diagnostic criteria applicable in vivo. 2 Yet SS has been reported as the only bleeding manifestation in some patients with CAA, especially if they present with transient clinical manifestations, e.g., seizures. 3 Regarding SS as another hemorrhagic manifestation of CAA, adding it as a criterion resulted in a diagnostic upgrading in 7 patients with CAA (2 of which had no other type of intracranial hemorrhage), whereas it did not lower the specificity of the Boston criteria for CAA-related hemorrhage.
There are some limitations to our study. 1) The difference in sensitivity between classic and modified Boston criteria was not significant, probably due to the limited number of cases. 2) A full postmortem examination was only available in 11 patients with CAA, but replacement of vessel walls with amyloid in hematoma or biopsy samples has been shown to be highly sensitive for CAA. e1 3) The inclusion criterion T2*w MRI may have contributed to a selection bias, as patients with large ICH often do not undergo MRI. 4) Due to the limited cases of histologically proven non-CAA forms of ICHs in which T2*w MRI was available, the control group was not ageand sex-matched to the CAA group, but younger on average. 5) In patients with isolated, localized supratentorial SS, there are several other causes of nontraumatic SAH which have to be taken into account as potential differential diagnosis, e.g., cortical vein thrombosis or vasculitis. e2 The sensitivity and specificity of SS for CAA have to be validated in larger prospective studies, and longitudinal follow-up studies of patients with SS should be performed.
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